JP2020533301A5 - - Google Patents

Download PDF

Info

Publication number
JP2020533301A5
JP2020533301A5 JP2020513648A JP2020513648A JP2020533301A5 JP 2020533301 A5 JP2020533301 A5 JP 2020533301A5 JP 2020513648 A JP2020513648 A JP 2020513648A JP 2020513648 A JP2020513648 A JP 2020513648A JP 2020533301 A5 JP2020533301 A5 JP 2020533301A5
Authority
JP
Japan
Prior art keywords
variant polypeptide
composition
mutated
composition according
agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020513648A
Other languages
English (en)
Japanese (ja)
Other versions
JP7795181B2 (ja
JP2020533301A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2018/049648 external-priority patent/WO2019051015A1/en
Publication of JP2020533301A publication Critical patent/JP2020533301A/ja
Publication of JP2020533301A5 publication Critical patent/JP2020533301A5/ja
Priority to JP2023133442A priority Critical patent/JP2023157959A/ja
Application granted granted Critical
Publication of JP7795181B2 publication Critical patent/JP7795181B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020513648A 2017-09-06 2018-09-06 インターロイキン－１８バリアントとその利用法 Active JP7795181B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023133442A JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762554605P 2017-09-06 2017-09-06
US62/554,605 2017-09-06
US201862652279P 2018-04-03 2018-04-03
US62/652,279 2018-04-03
PCT/US2018/049648 WO2019051015A1 (en) 2017-09-06 2018-09-06 VARIANTS OF INTERLEUKIN-18 AND METHODS OF USE

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023133442A Division JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Publications (3)

Publication Number Publication Date
JP2020533301A JP2020533301A (ja) 2020-11-19
JP2020533301A5 true JP2020533301A5 (https=) 2021-10-14
JP7795181B2 JP7795181B2 (ja) 2026-01-07

Family

ID=65517760

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020513648A Active JP7795181B2 (ja) 2017-09-06 2018-09-06 インターロイキン－１８バリアントとその利用法
JP2023133442A Pending JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023133442A Pending JP2023157959A (ja) 2017-09-06 2023-08-18 インターロイキン－１８バリアントとその利用法

Country Status (13)

Country Link
US (6) US20190070262A1 (https=)
EP (1) EP3678681A4 (https=)
JP (2) JP7795181B2 (https=)
KR (1) KR20200066623A (https=)
CN (1) CN111315395A (https=)
AU (2) AU2018330444B2 (https=)
BR (1) BR112020004389A2 (https=)
CA (1) CA3080492A1 (https=)
IL (2) IL305370A (https=)
MX (1) MX2020002542A (https=)
SG (1) SG11202001384TA (https=)
WO (1) WO2019051015A1 (https=)
ZA (1) ZA202307212B (https=)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12029778B2 (en) 2019-05-13 2024-07-09 Yale University Interleukin-18 mimics and methods of use
MX2022014239A (es) * 2020-05-12 2023-02-09 Regeneron Pharma Nuevos agonistas de il10 y metodos para su uso.
WO2022038417A2 (en) * 2020-08-19 2022-02-24 Bright Peak Therapeutics Ag Modified il-18 polypeptides and uses thereof
TW202233657A (zh) * 2020-11-02 2022-09-01 美商辛卡Ｉｌ １８公司 介白素-18變體及使用方法
CN116848130A (zh) * 2021-02-10 2023-10-03 国立大学法人长崎大学 新型人白细胞介素-18突变体及其用途
US20230146665A1 (en) 2021-07-27 2023-05-11 Xencor, Inc. Il-18-fc fusion proteins
JP7849832B2 (ja) 2021-08-06 2026-04-22 国立大学法人 長崎大学 がんの治療剤
WO2023114829A1 (en) * 2021-12-15 2023-06-22 Genentech, Inc. Stabilized il-18 polypeptides and uses thereof
WO2023118497A1 (en) * 2021-12-22 2023-06-29 Pieris Pharmaceuticals Gmbh Novel il-18 variants
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
CA3244053A1 (en) * 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag MODIFIED IL-18 POLYPEPTIDES
US20230263831A1 (en) * 2022-02-23 2023-08-24 Fred Hutchinson Cancer Center Methods for enhancing anti-tumor activity of exhausted t cells
JP2025508823A (ja) 2022-02-23 2025-04-10 ブライト ピーク セラピューティクス エージー 免疫抗原特異的ｉｌ－１８免疫サイトカイン及びその使用
PE20251671A1 (es) 2022-03-15 2025-06-30 Compugen Ltd Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer
EP4519678A4 (en) * 2022-05-05 2026-04-15 Hospital Espanol Auxilio Mutuo De Puerto Rico Inc TREATMENT METHODS FOR BLADDER CANCER
CA3261349A1 (en) * 2022-08-05 2024-02-08 Fuse Biotherapeutics Inc. IL-18 FUSING PROTEINS AND IL-18 PRODUCTION PROCESSES
WO2024044780A1 (en) * 2022-08-26 2024-02-29 Sutro Biopharma, Inc. Interleukin-18 variants and uses thereof
JP2025529313A (ja) * 2022-09-06 2025-09-04 ティージェイ バイオファーマ （シャンハイ） カンパニー， リミテッド Ｉｌ－１８バリアントポリペプチド
US20240209100A1 (en) * 2022-10-21 2024-06-27 Diagonal Therapeutics Inc. Heteromeric agonistic antibodies to il-18 receptor
US20240166705A1 (en) 2022-11-07 2024-05-23 Xencor, Inc. Il18-fc fusion proteins
CN118141897A (zh) 2022-12-07 2024-06-07 广州威溶特医药科技有限公司 Dr-18和溶瘤痘苗病毒在制备抗肿瘤药物中的应用
EP4646270A2 (en) * 2023-01-06 2025-11-12 Alector LLC Anti-il18 binding protein antibodies and methods of use thereof
TW202430560A (zh) * 2023-01-06 2024-08-01 美商拉森醫療公司 抗ｉｌ－１８ｂｐ抗體
IL321948A (en) 2023-01-06 2025-09-01 Lassen Therapeutics Inc Anti-IL-18 BP antibodies
AU2024211503A1 (en) * 2023-01-24 2025-07-31 Msd International Business Gmbh Methods and compositions for combination therapy
CN121666402A (zh) * 2023-06-09 2026-03-13 默克专利股份公司 Il-18模拟物
TW202515608A (zh) 2023-06-26 2025-04-16 以色列商坎布根有限公司 Ｉｌ—１８ｂｐ拮抗抗體及其於癌症治療之單一療法及組合療法的用途
WO2025015103A1 (en) * 2023-07-10 2025-01-16 The Children's Hospital Of Philadelphia Methods for modulating activity of il-18 for treatment of cd4+ t cell mediated autoimmunity and immunopathology
WO2025041102A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Targeted immune activation with il-18 immunocytokines
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
US20250188166A1 (en) 2023-08-23 2025-06-12 Bright Peak Therapeutics Ag Il-18 polypeptides fused to immune cell antigen specific binding polypeptides and uses thereof
AU2024352706A1 (en) 2023-09-28 2026-04-02 Prokarium Limited Interleukin 18 variants
WO2025085447A1 (en) 2023-10-17 2025-04-24 Xencor, Inc. Pd-1 targeted il18-fc fusion proteins
CN120093897A (zh) * 2023-12-04 2025-06-06 广州威溶特医药科技有限公司 Dr-18和单纯疱疹病毒在制备抗肿瘤药物中的应用
CN120189493A (zh) 2023-12-22 2025-06-24 广州威溶特医药科技有限公司 Dr-18和m1病毒在制备抗肿瘤药物中的应用
US12134635B1 (en) 2023-12-29 2024-11-05 Sonnet BioTherapeutics, Inc. Interleukin 18 (IL-18) variants and fusion proteins comprising same
WO2025151273A1 (en) * 2024-01-08 2025-07-17 Adimab, Llc Il-18 polypeptides and uses thereof
WO2025185694A1 (en) * 2024-03-06 2025-09-12 TJ Biopharma (Shanghai) Co., Ltd. Constructs comprising il-18 components and uses thereof
WO2025242835A1 (en) 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025251226A1 (en) 2024-06-05 2025-12-11 Nuwacell Biotechnologies Co., Ltd. Use of interleukin-21 and interleukin-15 for enhancing serial killing of natural killer cell for cell therapy against target cell

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US6713279B1 (en) 1995-12-07 2004-03-30 Diversa Corporation Non-stochastic generation of genetic vaccines and enzymes
US6479258B1 (en) 1995-12-07 2002-11-12 Diversa Corporation Non-stochastic generation of genetic vaccines
US6790442B1 (en) 1996-06-27 2004-09-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-γ
EP0816499A3 (en) * 1996-06-27 1999-10-27 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Genomic DNA encoding a polypeptide capable of inducing the production of interferon-gamma
JP4024366B2 (ja) 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
JP3955352B2 (ja) * 1997-02-25 2007-08-08 株式会社林原生物化学研究所 破骨細胞形成阻害剤
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
JP2001266941A (ja) 2000-03-17 2001-09-28 Sony Corp ゲル電解質電池の製造方法
AU7516601A (en) * 2000-06-02 2001-12-17 Susan B Dillon Methods of treating viral diseases with il-18 and il-18 combinations
PL208592B1 (pl) 2000-06-15 2011-05-31 Smithkline Beecham Corp Sposób wytwarzania aktywnego ludzkiego polipeptydu IL-18 z ludzkiego polipeptydu prekursora IL-18
US6818444B2 (en) 2000-08-04 2004-11-16 Heska Corporation Canine and feline proteins, nucleic acid molecules and uses thereof
ATE315647T1 (de) * 2001-03-08 2006-02-15 Ares Trading Sa Interleukin -18 mutantenproteine, deren herstellung und verwendung
ATE490968T1 (de) 2001-05-04 2010-12-15 Cornell Res Foundation Inc Schnell spaltbares sumofusionsprotein- expressionssystem für schwer zu exprimierende proteine
AU2002326961A1 (en) 2001-10-10 2003-04-22 Centocor, Inc. Nucleic acid vaccines using tumor antigen encoding nucleic acids with cytokine adjuvant encoding nucleic acid
WO2003057821A2 (en) 2001-10-26 2003-07-17 Centocor, Inc. Mut-il-18 or mut-il-18r proteins, antibodies, compositions, methods and uses
US6800479B2 (en) 2001-12-11 2004-10-05 Samyang Genex Corporation Recombinant adenoviruses expressing interleukin-18 protein and gene therapy using them
US7220576B2 (en) 2002-01-07 2007-05-22 Lifesensors, Inc. Methods and compositions for protein expression and purification
CA2472477C (en) 2002-01-07 2012-03-20 Lifesensors, Inc. Methods and compositions for protein expression and purification
US7253260B2 (en) 2002-04-17 2007-08-07 Smithkline Beecham Corporation Human IL-18 crystal structure
AU2003280017A1 (en) * 2002-06-27 2004-01-19 Smithkline Beecham Corporation Methods of treating or preventing ibd with il-18
MXPA05003869A (es) * 2002-10-08 2005-06-22 Ares Trading Sa El uso de citocina capaz de enlazarse a la proteina de union a interleucina-18, y de inhibir la actividad de una segunda citocina.
ATE459647T1 (de) 2003-04-15 2010-03-15 Glaxosmithkline Llc Humane il-18 substitutionsmutanten und deren konjugate
US20080076708A1 (en) * 2003-05-13 2008-03-27 Valter Altarocca Active Variants of the Il-18 Binding Protein and Medical Uses Thereof
AU2004254600A1 (en) 2003-06-26 2005-01-13 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
DE602004031341D1 (de) 2003-07-21 2011-03-24 Transgene Sa Multifunktionelle cytokine
DK1648931T3 (da) * 2003-07-21 2011-03-07 Transgene Sa Multifunktionelle cytokiner
WO2005075648A1 (en) * 2004-01-28 2005-08-18 Gifu University Interleukin-18 mutant proteins
EP1793859B1 (en) 2004-08-20 2009-03-25 Smithkline Beecham Corporation Treatment of oral and intestinal mucositis by administering human il-18
US8119369B2 (en) 2004-12-30 2012-02-21 Lifesensors, Inc. Human SUMO-3 for enhancing protein expression
EP2059253A4 (en) 2006-09-14 2011-09-14 Univ Pennsylvania MODULATION OF T LYMPHOCYTES REGULATORS BY HUMAN IL-18
AU2007342011A1 (en) 2006-12-29 2008-07-10 Lifesensors, Inc. Methods and compositions for enhanced protein expression and purification
WO2009062102A2 (en) 2007-11-07 2009-05-14 Genentech, Inc. Compositions and methods for treatment of microbial disorders
CN101960209B (zh) 2008-02-27 2012-11-07 夏普株式会社 照明装置、显示装置和电视接收装置
US8034910B2 (en) 2008-05-06 2011-10-11 Academia Sinica, Taiwan SUMO fusion protein expression system for producing native proteins
CN101993495B (zh) 2009-08-12 2013-07-24 上海近岸科技有限公司 一种蛋白质混合物及其制备方法
US9316417B2 (en) 2012-06-29 2016-04-19 Sunpower Corporation Framing system for mounting solar collecting devices
BR112015002091A2 (pt) 2012-08-02 2017-12-12 Hoffmann La Roche método para a produção de um polipeptídeo, polipeptídeo, uso de um polipeptídeo e composição
US9376489B2 (en) * 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US10646548B2 (en) 2013-10-08 2020-05-12 Georgia State University Research Foundation, Inc. Compositions including IL-18 and IL-22 and their use in anti-viral therapies
US10882905B2 (en) 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
RU2749113C2 (ru) 2015-04-22 2021-06-04 Куревак Аг Содержащая рнк композиция для лечения опухолевых заболеваний
WO2017102010A1 (en) * 2015-12-17 2017-06-22 Biontech Rna Pharmaceuticals Gmbh Novel cytokine fusion proteins
CA3011374A1 (en) 2016-02-05 2017-08-10 Washington University Compositions and methods for targeted cytokine delivery
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
ITUA20161992A1 (it) 2016-03-24 2017-09-24 Plico Biotech Inc Sumo e suoi utilizzi
AU2017305524B2 (en) 2016-08-04 2024-09-26 Memorial Sloan-Kettering Cancer Center Compositions and methods for immunotherapy
JP2019529499A (ja) 2016-09-30 2019-10-17 ベイラー カレッジ オブ メディスンＢａｙｌｏｒ Ｃｏｌｌｅｇｅ Ｏｆ Ｍｅｄｉｃｉｎｅ 組織指向性発現を用いた抗体ベースの遺伝子治療
TWI591177B (zh) 2016-10-27 2017-07-11 中化合成生技股份有限公司 一種胰高血糖素胜肽－２（ｇｌｐ－２）類似物的製備方法
CN117986384A (zh) 2017-03-06 2024-05-07 艾尔特生物科技公司 与il-12和il-18的基于il-15的融合物
US20210017247A1 (en) 2017-07-03 2021-01-21 Torque Therapeutics, Inc. Fusion Molecules Targeting Immune Regulatory Cells and Uses Thereof
EP3788150A4 (en) 2018-05-04 2022-01-26 Sigma-Aldrich Co. LLC PRODUCTION OF RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS
US11518792B2 (en) 2018-08-30 2022-12-06 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
CA3109361A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Single-chain and multi-chain chimeric polypeptides and uses thereof
US11401324B2 (en) 2018-08-30 2022-08-02 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
KR20210127924A (ko) 2019-01-04 2021-10-25 레퍼토리 아임뮨 메디신스, 인크. 고다양성 펩티드 라이브러리의 제조 및 단백질 폴딩의 촉진 방법
KR20220023988A (ko) 2019-05-14 2022-03-03 웨어울프 세라퓨틱스, 인크. 분리 모이어티 및 이의 사용 방법
US20220226464A1 (en) 2019-05-28 2022-07-21 Massachusetts Institute Of Technology Methods and compositions for modulating immune responses
WO2020243729A1 (en) 2019-05-31 2020-12-03 Children's National Medical Center Cytokine cocktails for selective expansion of t cell subsets
EP4013857A1 (en) 2019-08-13 2022-06-22 King's College London Immunoresponsive cells armoured with spatiotemporally restricted activity of cytokines of the il-1 superfamily
WO2021072211A1 (en) 2019-10-09 2021-04-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for treating cytotoxic t cell resistant tumors
KR20230084470A (ko) 2020-08-14 2023-06-13 카이트 파마 인코포레이티드 면역 세포 기능의 향상
WO2022038417A2 (en) 2020-08-19 2022-02-24 Bright Peak Therapeutics Ag Modified il-18 polypeptides and uses thereof
TW202233657A (zh) 2020-11-02 2022-09-01 美商辛卡Ｉｌ １８公司 介白素-18變體及使用方法
KR20240007179A (ko) 2021-04-30 2024-01-16 셀렉티스 에스.에이. 고형 종양 암 면역 요법을 위한 새로운 항-muc1 car 및 유전자 편집된 면역세포
WO2022260968A1 (en) 2021-06-10 2022-12-15 Chimera Bioengineering, Inc. Compositions and methods for activating natural killer cells

Similar Documents

Publication Publication Date Title
JP2020533301A5 (https=)
JP7744479B2 (ja) 抗ヒトパピローマウイルス１６ ｅ７ ｔ細胞受容体
JP7223822B2 (ja) 抗ヒトパピローマウイルス１６ ｅ６ ｔ細胞受容体
US12312391B2 (en) Anti-mutated KRAS T cell receptors
Klein et al. Cergutuzumab amunaleukin (CEA-IL2v), a CEA-targeted IL-2 variant-based immunocytokine for combination cancer immunotherapy: Overcoming limitations of aldesleukin and conventional IL-2-based immunocytokines
Hahn et al. The future of immune checkpoint cancer therapy after PD-1 and CTLA-4
GB2617483A (en) Interleukin-18 variants and methods of use
CN113784976B (zh) 用于鉴定抗原特异性t细胞的组合物和方法
JP2022159548A5 (https=)
JP2020508691A (ja) Ｉｌ−１２及びｉｌ−１８へのｉｌ−１５系融合
JPWO2020113164A5 (https=)
JPWO2022094473A5 (https=)
CN111601817A (zh) 分泌il-33的免疫应答细胞及其用途
AU2020373899A1 (en) Drug for treating cancer, combination drug, drug composition, immune responsive cell, nucleic acid delivery vehicle, and product
US20250302953A1 (en) Methods of treating patients exhibiting a prior failed therapy with hypoimmunogenic cells
Patterson et al. Control of established colon cancer xenografts using a novel humanized single chain antibody-streptococcal superantigen fusion protein targeting the 5T4 oncofetal antigen
CN114980907A (zh) 增强细胞癌症治疗的t细胞死亡相关基因8(tdag8)调节
JP2020535832A (ja) マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
EP4157863A2 (en) Engineered immune cells, compositions and methods thereof
CN115279389A (zh) 新型显性负性Fas多肽、包含其的细胞及其用途
US20240424098A1 (en) Modified immune cells and methods of use thereof
RU2020112538A (ru) Варианты интерлейкина-18 и способы их применения
CN120758457A (zh) 改造的免疫细胞、靶向Mettl13基因的gRNA和应用
CA2968399C (en) Anti-mutated kras t cell receptors
Khana et al. Application of CAR T cells for